For FY2026 interim period (Q2), revenue was 503,090 thousand yen, operating loss 767,606 thousand yen, ordinary loss 760,604 thousand yen, and interim net loss 762,153 thousand yen. Compared with the same period prior year, revenue increased to 28,546 thousand yen, and net loss narrowed. In regulatory matters, OBP-301 price approval and listing are proceeding. There is no dividend forecast, and share issuance reflects capital increases due to stock option exercises and a capital reduction. No forward-looking guidance has been disclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncolys BioPharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4588-20260807-01.pdf","jir_short_summary":"For FY2026 interim period (Q2), revenue was 503,090 thousand yen, operating loss 767,606 thousand yen, ordinary loss 760,604 thousand yen, and interim net loss 762,153 thousand yen. Compared with the same period prior year, revenue increased to 28,546 thousand yen, and net loss narrowed. In regulatory matters, OBP-301 price approval and listing are proceeding. There is no dividend forecast, and share issuance reflects capital increases due to stock option exercises and a capital reduction. No forward-looking guidance has been disclosed.","jir_summary":"### Performance overview\nOncolys Biopharma's FY2026 interim second quarter results show revenue of 503,090 thousand yen, with operating loss, ordinary loss, and interim net loss all in the red. Revenue grew notably versus the same period last year, and the extent of losses narrowed. However, the financial summary does not disclose forecasts, and earnings guidance is not yet public. In regulatory matters, OBP-301 price approval and price listing are planned, with preparations for product launch underway.\n\n### Capital and financial highlights\nAt interim period end, equity ratio stood at 72.1%, total assets 4,510,606 thousand yen. Paid-in capital and capital surplus were reduced to reflect the exercise of stock acquisition rights and a capital reduction as of May 31, 2026, with remaining earnings carried forward. Outstanding shares were 29,319,700, with a period-average of 29,284,197. Cash flows: operating activities \u25b31,017,309 thousand yen, investing activities \u25b331,525 thousand yen, financing activities +496,622 thousand yen, ending cash and cash equivalents of 2,941,682 thousand yen.","jir_financial_highlights":"Revenue: 503,090\u5343\u5186 (\u524d\u5e74\u540c\u671f\u6bd4 +474,544\u5343\u5186)\nOperating loss: \u25b3767,606\u5343\u5186 (\u524d\u5e74\u540c\u671f \u25b31,267,127\u5343\u5186\u304b\u3089\u6539\u5584)\nOrdinary loss: \u25b3760,604\u5343\u5186 (\u524d\u5e74\u540c\u671f \u25b31,311,654\u5343\u5186\u304b\u3089\u6539\u5584)\nInterim net loss: \u25b3762,153\u5343\u5186 (\u524d\u5e74\u540c\u671f \u25b31,313,230\u5343\u5186\u304b\u3089\u6539\u5584)\nTotal assets: 4,510,606\u5343\u5186 (\u524d\u4e8b\u696d\u5e74\u5ea6\u672b\u6bd4 \u25b345,273\u5343\u5186)","jir_category":"","jir_hashtags":"#OncolysBiopharma, #FinancialSummary, #DrugDelivery, #OBP301","jir_key_figures":"Revenue: 503,090\u5343\u5186\uff08\u524d\u5e74\u540c\u671f 28,546\u5343\u5186\uff09\nOperating loss: \u25b3767,606\u5343\u5186\uff08\u524d\u5e74\u540c\u671f \u25b31,267,127\u5343\u5186\uff09\nInterim net loss: \u25b3762,153\u5343\u5186\uff08\u524d\u5e74\u540c\u671f \u25b31,313,230\u5343\u5186\uff09","jir_meta_title":"Oncolys Biopharma Ltd. FY2026 Q2 Financial Summary | Revenue 5.04 hundred million yen; narrowing losses","jir_meta_description":"Summary of Oncolys Biopharma's FY2026 Q2 Financial Summary. Revenue 503,090 thousand yen, operating loss 767,606 thousand yen; OBP-301 price decision and preparation for sales ongoing. Dividends not disclosed.","jir_og_title":"Oncolys Biopharma | FY2026 Q2 Financial Summary","jir_og_description":"Summary of Oncolys Biopharma's financial summary. Revenue 503,090 thousand yen; operating loss 767,606 thousand yen; OBP-301 approval and price listing progressing. Future prospects not disclosed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-99681","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n